Evidence map›Paper›PMID 25433021›Full record

ReviewEuropean heart journal2015

Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Justin C Mason, Peter Libby

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 187 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.Climacteric : the journal of the International Menopause Society · 2021
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Review
  20. Article

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Justin C MasonVascular Sciences Unit and Rheumatology Section, Imperial Centre for Translational and Experimental Medicine, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK justin.mason@imperial.ac.uk.
Peter LibbyDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Funding

Molecular Determinants of Arterial Remodeling in AtherogenesisR01HL080472 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LIBBY, PETER · 2005 to 2018
$5.0M
British Heart FoundationNHLBI NIH HHS HL080472
6 · The paper itself

Abstract

A variety of systemic inflammatory rheumatic diseases associate with an increased risk of atherosclerotic events and premature cardiovascular (CV) disease. Although this recognition has stimulated intense basic science and clinical research, the precise nature of the relationship between local and systemic inflammation, their interactions with traditional CV risk factors, and their role in accelerating atherogenesis remains unresolved. The individual rheumatic diseases have both shared and unique attributes that might impact CV events. Understanding of the positive and negative influences of individual anti-inflammatory therapies remains rudimentary. Clinicians need to adopt an evidence-based approach to develop diagnostic techniques to identify those rheumatologic patients most at risk of CV disease and to develop effective treatment protocols. Development of optimal preventative and disease-modifying approaches for atherosclerosis in these patients will require close collaboration between basic scientists, CV specialists, and rheumatologists. This interface presents a complex, important, and exciting challenge.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, RheumatoidBiological FactorsBiomarkersCoronary Artery DiseaseGoutHumansImmunosuppressive AgentsLupus Erythematosus, SystemicRheumatic DiseasesRisk FactorsVasculitisAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsBiological FactorsBiomarkersImmunosuppressive AgentsAtherosclerosisCoronary artery diseaseInflammationRheumatic diseaseRheumatoid arthritisRisk factorsSystemic lupus erythematosus

Identifiers

PMID25433021
PMCPMC4340364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.